BACKGROUND: The present experiments sought to determine whether cilostazol, a
selective inhibitor of cyclic adenosine monophosphate (cAMP) phosphodiesterase 3 …

Purpose Azelnidipine has recently been recognized in vascular remodeling. However, the
effects of azelnidipine on aneurysmal disease have not yet been studied. The aim of this …

Agents to inhibit the renin-angiotensin system have been reported to suppress the
progression of abdominal aortic aneurysm (AAA). However, the effects of calcium channel …

Objective—Abdominal aortic aneurysm (AAA) is a permanent dilation of the abdominal aorta
associated with rupture, which frequently results in fatal consequences. AAA tissue is …

In the present study we sought to determine the effect of CoCl2, an inhibitor of PHD (prolyl
hydroxylase domain protein), on the development of AAA (abdominal aortic aneurysm). AAA …

Background Although systemic hypertension is closely associated with aortic aneurysm (AA)
formation, there are many patients with AA without hypertension. In these patients, an …

OBJECTIVE: An ideal pharmaceutical treatment for abdominal aortic aneurysm (AAA) is to
prevent aneurysm formation and development (further dilatation of pre-existing aneurysm) …

Background The purpose of the present study was to evaluate the effect of a new
angiotensin converting enzyme inhibitor perindopril on the formation of experimental …

Abdominal aortic aneurysm (AAA) is a common life-threatening condition characterized by
exacerbated inflammation and the generation of reactive oxygen species. Pharmacological …

OBJECTIVE: Proinflammatory cytokines and matrix metalloproteinases (MMPs) are
prominent mediators of the connective tissue destruction that characterizes abdominal aortic …